Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer

NCT07811895 · Not yet recruiting

Last updated 2026-09-22

This clinical trial is testing whether the medication tirzepatide, given to obese women before a frozen embryo transfer, affects the likelihood of a successful pregnancy.

Status Not yet recruiting Approved but enrollment has not started.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 1,510 people Planned (estimated).

Who can join Ages 20–40 · female only

Timeline Started 2026-09 · est. completion 2030-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07811895 ↗

Description as written by the study sponsor.

To evaluate the efficacy and safety of Dual GIP/GLP-1 receptor agonist pretreatment on reproductive outcomes in obese women before frozen embryo transfer.

Treatments tested

Dual GIP/GLP-1 receptor agonist also known as Tirzepatide Drug

16 weeks treatment

Main thing measured	Good birth outcome rate
Sponsor	RenJi Hospital
Conditions studied	Tirzepatide, Frozen Embryo Transfer, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07811895 ↗